Erasca, Inc. (ERAS) Stock: Price, Forecast & Analyst Target
Erasca, Inc. (ERAS) — MoonshotScore 63/100 (Fair band), calculated Oct 9, 2026. Price $15.46 (+9.49%), as of the Oct 8, 2026 trading session; market cap $5.37B. Expected results Nov 11, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 19.98× (market value Oct 8, 2026; cash Jun 30, 2026) · expected results Nov 11, 2026
Erasca, Inc. · ERAS · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Erasca, Inc. is a San Diego clinical-stage biopharmaceutical developer focused on oral targeted oncology candidates in the RAS/MAPK pathway for difficult tumor settings. The core question is whether the company can keep advancing that clinical program stack through an expected sequence of costly development phases without shrinking financial flexibility. The reported results do not include meaningful commercial sales, so valuation is being built on development progress and liquidity discipline rather than revenue traction.
Price as of Oct 8, 2026
Key Statistics
MoonshotScore v2 · Erasca (ERAS)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but weak quality; the market is already moving on it. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z 34.55 · Piotroski F 1
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair |
The score moved from 62 in the stored Oct 7, 2026 snapshot to 63 in the current publication computed Oct 9, 2026 (+1); the largest pillar moves were Momentum +4 and Growth Durability +1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $15.46 |
| Change on the day | +9.49% |
| 52-week range | $2.10–$24.28 |
| Market capitalisation | $5.37B |
| Shares traded on the day | 4.85M |
| Beta (volatility vs the S&P 500) | 0.65 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Erasca (ERAS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 6, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 9, 2026, except a card that shows its own read date.
Watch the ERAS film — every key number, told as a short cinematic story
~2 min · open the film
What is Erasca (ERAS), and what does it report?
Short answer · as of
The business is a drug discovery and development engine, not a healthcare service firm. Its pipeline is built from internal oral candidates aimed at specific signaling paths in oncology, including a brain-access strategy for recurrent glioblastoma.
Research dated 2026-09-13.
The business is a drug discovery and development engine, not a healthcare service firm. Its pipeline is built from internal oral candidates aimed at specific signaling paths in oncology, including a brain-access strategy for recurrent glioblastoma.
The reporting framework therefore reflects development economics: quarterly and annual statements remain revenue-light while losses accumulate and expense lines are dominated by research activity and broad operating support.
What do the latest results show for Erasca (ERAS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Research dated 2026-09-13.
What changed in the latest period is a sharp shift in headline loss versus the prior period even though core operating losses are still deeply negative, which points to movement outside recurring operating spend rather than a full change in trial economics.
Separately, the filing stream for the latest cycle still carries the standard results-and-financial-condition disclosure channel, and the most recent EPS outcome stood below the latest estimate while prior periods were nearer to consensus; that sets the immediate operating context for follow-through.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $35.90M Jun 30, 2026
- Latest quarter · SG&A
- $11.72M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$47.62M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $35.90M | $11.72M | −$47.62M |
| Mar 31, 2026 | Not available | $27.27M | $10.65M | −$37.91M |
| Dec 31, 2025 | Not available | $23.24M | $9.36M | −$32.60M |
| Sep 30, 2025 | Not available | $22.47M | $10.07M | −$34.55M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Below estimate Aug 12, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 12, 2026 | Not available | Not available | −$0.1400 | −$0.1114 |
| May 11, 2026 | Not available | Not available | −$0.6000 | −$0.1115 |
| Mar 12, 2026 | Not available | Not available | −$0.1000 | −$0.1100 |
| Nov 12, 2025 | Not available | Not available | −$0.1100 | −$0.1100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$44M | -$0.14 (diluted) |
| Q1 FY2026 | $0 | -$183M | -$0.60 (diluted) |
| Q4 FY2025 | $0 | -$29M | -$0.10 (diluted) |
| Q3 FY2025 | $0 | -$31M | -$0.11 (diluted) |
What are the financial strengths and risks for Erasca (ERAS)?
Short answer
Cash and short-term investments were $268.74M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$27.27M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Financial strength is largely structural: cash and short-term investments sit above debt and total liabilities, and the balance sheet snapshot is not constrained by long-duration investment commitments.
The recurring risk is operational: every reported period in the cash-flow series is negative, and sustained burn in that environment compresses runway quickly unless development milestones arrive in sequence with new financing support.
Data-derived red flags
- Negative return on equity (-80.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$27.27M Jun 30, 2026
- Previous quarter · operating cash flow
- −$27.38M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$27.27M | −$10,000 |
| Mar 31, 2026 | −$27.38M | −$40,000 |
| Dec 31, 2025 | −$21.71M | −$10,000 |
| Sep 30, 2025 | −$21.66M | −$10,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Erasca (ERAS)?
Short answer · as of
The next earnings report is expected on Nov 11, 2026.
Research dated 2026-09-13.
The next earnings checkpoint is where trend quality is most likely to change; until then, cash and loss path has to be interpreted as the leading barometer of execution.
The next read is most useful when the headline loss, operating cash flow, and accompanying filing signals move in the same direction, because that alignment is what signals genuine operating change rather than one-off accounting effects.
How does Erasca compare with its peers?
Short answer
Erasca's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
For peer context, the real differentiator is mechanism and stage: ERAS is tied to a narrow group of RAS/MAPK-focused oral candidates with no broad commercial service base, so peer comparisons that stop at sector labels miss the dependency on specific oncology inflection points.
Owner structure is also unusually concentrated toward institutions, which means public information flow from filings and clinical updates can move sentiment in ways that do not match companies with immediate commercial revenue and recurring user demand.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1169.93 Oct 8, 2026 | $1.09T | 97 5-pillar Oct 9, 2026 | |
| $295.00 Oct 8, 2026 | $5.91B | 96 5-pillar Oct 9, 2026 | |
| $43.60 Oct 8, 2026 | $3.48B | 96 5-pillar Oct 9, 2026 | |
| $27.50 Oct 8, 2026 | $7.77B | 89 5-pillar Oct 9, 2026 | |
| $24.49 Oct 8, 2026 | $3.06B | 87 5-pillar Oct 9, 2026 | |
| $407.44 Oct 8, 2026 | $220B | 85 5-pillar Oct 9, 2026 | |
| $19.58 Oct 8, 2026 | $3.35B | 76 5-pillar Oct 9, 2026 | |
| $139.91 Oct 8, 2026 | $9.00B | 76 5-pillar Oct 9, 2026 | |
| $152.52 Oct 8, 2026 | $6.11B | 69 5-pillar Oct 9, 2026 | |
| $126.63 Oct 8, 2026 | $5.29B | 66 5-pillar Oct 9, 2026 | |
| $77.28 Oct 8, 2026 | $4.66B | 66 5-pillar Oct 9, 2026 | |
| $53.34 Oct 8, 2026 | $8.17B | 66 5-pillar Oct 9, 2026 | |
| Erasca (ERAS) — this page | $15.46 | $5.37B | 63 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $16.00 – $30.00
- Consensus target
- $22.50
- Median target
- $21.50
Consensus record · Captured .
Measured against a quoted price of $15.46 (as of Oct 8, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Aug 10, 2026
- Transactions
- 7
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 0
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 90.7% Period end Jun 30, 2026
- Previous quarter · ownership
- 89.9% Prior to period end Jun 30, 2026
- Reporting holders
- 274 Period end Jun 30, 2026
- Previous quarter · holders
- 234 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 |
| T. Rowe Price Investment Management, INC. | 21,185,839 |
| Blackrock, INC. | 21,154,146 |
| Rtw Investments, LP | 17,946,754 |
| Vr Adviser, LLC | 17,891,812 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Erasca (ERAS)?
- Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
- Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
- Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Frazier Life Sciences Management L.P. Has $457.55 Million Stock Position in Erasca, Inc. $ERAS
What Investors Ask About Erasca (ERAS) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does ERAS generate revenue now if products are not yet commercialized?
The current filings show no product revenue in both quarterly and annual reporting windows. Performance today is therefore driven by research and operating spend rather than sales growth.
Which ERAS program is being developed for recurrent glioblastoma with central nervous system penetration?
The company’s disclosed pipeline identifies the EGFR-based oral program as the recurrent glioblastoma asset with CNS penetration, while other oral candidates focus on ERK-pathway and SHP-family approaches. This is a direct indicator that the value chain remains anchored in trial progress across specific candidates, not in marketed therapy scale.
What could erode ERAS’s cash position most quickly before the next clinical catalyst?
The most sensitive variable is persistent negative operating cash flow combined with no offsetting commercial inflows, since this company is still pre-revenue. That path is what determines runway extension or contraction and therefore the distance to any financing decision.
How should investors separate core execution from accounting noise in the next report?
Watch the next quarter’s EPS and the operating-loss trend together with operating cash flow and filing signals. Core execution is stronger when these move in the same direction. If one line moves sharply while the others lag, it usually means the headline is being affected by non-core items rather than a durable change in development spending pace.
What is the ERAS stock price today?
The last price recorded on this page for Erasca, Inc. (ERAS) is $15.46, as of the Oct 8, 2026 trading session (source: Financial Modeling Prep (FMP) quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ERAS price target?
The analyst consensus price target for Erasca, Inc. (ERAS) is $22.50 (range $16.00 to $30.00, median $21.50), per FMP data captured Oct 9, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.3-codex-spark) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (67 figures)
The 67 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 3115 Merryfield ROW, Third Floor, SAN Diego, CA, 92121 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "3115 Merryfield Row, San Diego, CA, 92121, US". |
FMP — 59 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 11, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $15.46 | FMP | Financial Modeling Prep (FMP) quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. | |
px.change | Change on the day | +9.49% | FMP | Financial Modeling Prep (FMP) quote | |
px.mcap | Market capitalization | $5.37B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-08. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.34 | FMP | Financial Modeling Prep (FMP) quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $2.10–$24.28 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 4.85M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.65 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Jonathan E. Lim | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 103 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result −$122.76M; FY2022 revenue $0.00, net result −$242.80M; FY2023 revenue $0.00, net result −$125.04M; FY2024 revenue $0.00, net result −$161.65M; FY2025 revenue $0.00, net result −$124.55M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $35.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $11.72M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$47.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $27.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $10.65M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$37.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $23.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $9.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$32.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $22.47M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $10.07M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$34.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-12.eps_actual | EPS · reported — report date 2026-08-12 | −$0.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-12.eps_estimated | EPS · estimate — report date 2026-08-12 | −$0.1114 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_actual | EPS · reported — report date 2026-05-11 | −$0.6000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_estimated | EPS · estimate — report date 2026-05-11 | −$0.1115 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-12.eps_actual | EPS · reported — report date 2026-03-12 | −$0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-12.eps_estimated | EPS · estimate — report date 2026-03-12 | −$0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_actual | EPS · reported — report date 2025-11-12 | −$0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_estimated | EPS · estimate — report date 2025-11-12 | −$0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $268.74M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$27.27M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $44.71M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 13.30× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$27.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$27.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$40,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$21.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$21.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $16.00 – $30.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 9, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $22.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 9, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $21.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 9, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 7 transactions · 0 purchases, 0 sales, 7 other transactions · 7 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Aug 10, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 90.7% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 89.9% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 274 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 234 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Frazier Life Sciences Management, L.P. — shares in provider snapshot | 24,975,188 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 21,185,839 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 21,154,146 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Rtw Investments, LP — shares in provider snapshot | 17,946,754 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vr Adviser, LLC — shares in provider snapshot | 17,891,812 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-13 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 34.55 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-09 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -80.4% · ROA -66.0% · current ratio 8.29 · earnings yield -5.2% · free-cash-flow yield -1.6% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 19.98× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $268.74M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-08. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-12.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.1400) with the recorded estimate (−$0.1114) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 63 of 100 · Fair · pillars 39 / 81 / 50 / 65 / 81 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 62 (stored snapshot Oct 7, 2026) → 63 (current publication computed Oct 9, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-12. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-12.eps_actual.comparison,earn.history.depth.2026-08-12.eps_actual,earn.history.depth.2026-08-12.eps_estimated,earn.history.depth.2026-05-11.eps_actual,earn.history.depth.2026-05-11.eps_estimated,earn.history.depth.2026-03-12.eps_actual,earn.history.depth.2026-03-12.eps_estimated,earn.history.depth.2025-11-12.eps_actual,earn.history.depth.2025-11-12.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Erasca, Inc. | 2026-03-12 | OFFICIAL | SEC EDGAR — 10-K filed 2026-03-12 |
| Business description | Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash, investments and debt | Total debt: $44.71M; Liquidity basis: cash and short-term investments; Total liabilities: $73.19M; Cash and short-term investments: $268.74M; Cash and investments: $268.70M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash runway cross-check (ours) | Years: 2.7; Method: cash and short-term investments of $268.7M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($98.6M per year); Reaches: 2029-03; Cash basis: cash and short-term investments; Cash: $268.70M; Annualized cash use: $98.60M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Recent SEC filings |
| 2026-08-24 | OFFICIAL | SEC EDGAR filer submissions |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-12 | FMP | Financial Modeling Prep (FMP) earnings |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $268.70M; Cash and short-term investments: $268.70M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $268.70M; Decline: $50.20M; Opening balance: $318.90M; Average change per period: $7.20M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Next earnings report | Date: 2026-11-11; EPS estimate: -$0.14 per share The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Most recent periodic reports | 2026-08-11 | OFFICIAL | SEC EDGAR filer submissions | |
| Institutional ownership (13F) | Holders: 274; Quarter: 2026-06-30; Ownership: 90.7%; Holders previous quarter: 234; Ownership previous quarter: 89.9 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
Data provided for informational purposes only.